Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Authors:
- Colin C. PritchardCPColin C. Pritchard
- Joaquin MateoJMJoaquin Mateo
- Michael F. WalshMWMichael F. Walsh
- Navonil De SarkarNSNavonil De Sarkar
- Wassim AbidaWAWassim Abida
- Himisha BeltranHBHimisha Beltran
- Andrea GarofaloAGAndrea Garofalo
- Roman GulatiRGRoman Gulati
- Suzanne CarreiraSCSuzanne Carreira
- Rosalind EelesRERosalind Eeles
- Olivier ElementoOEOlivier Elemento
- Mark A. RubinMRMark A. Rubin
Top Cited Papers
- 4 August 2016
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (5) , 443-453
Abstract
Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established. We recruited 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis. We isolated germline DNA and used multiplex sequencing assays to assess mutations in 20 DNA-repair genes associated with autosomal dominant cancer-predisposition syndromes. A total of 84 germline DNA-repair gene mutations that were presumed to be deleterious were identified in 82 men (11.8%); mutations were found in 16 genes, including BRCA2 (37 men [5.3%]), ATM (11 [1.6%]), CHEK2 (10 [1.9% of 534 men with data]), BRCA1 (6 [0.9%]), RAD51D (3 [0.4%]), and PALB2 (3 [0.4%]). Mutation frequencies did not differ according to whether a family history of prostate cancer was present or according to age at diagnosis. Overall, the frequency of germline mutations in DNA-repair genes among men with metastatic prostate cancer significantly exceeded the prevalence of 4.6% among 499 men with localized prostate cancer (P<0.001), including men with high-risk disease, and the prevalence of 2.7% in the Exome Aggregation Consortium, which includes 53,105 persons without a known cancer diagnosis (P<0.001). In our multicenter study, the incidence of germline mutations in genes mediating DNA-repair processes among men with metastatic prostate cancer was 11.8%, which was significantly higher than the incidence among men with localized prostate cancer. The frequencies of germline mutations in DNA-repair genes among men with metastatic disease did not differ significantly according to age at diagnosis or family history of prostate cancer. (Funded by Stand Up To Cancer and others.)Keywords
This publication has 39 references indexed in Scilit:
- Screening for Prostate Cancer Decreases the Risk of Developing Metastatic Disease: Findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC)European Urology, 2012
- HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)Human Genetics, 2012
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- Germline BRCA1 mutations increase prostate cancer riskBritish Journal of Cancer, 2012
- BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patientsBritish Journal of Cancer, 2011
- Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencingProceedings of the National Academy of Sciences, 2010
- GermlineBRCAMutations Denote a Clinicopathologic Subset of Prostate CancerClinical Cancer Research, 2010
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003